{"protocolSection": {"identificationModule": {"nctId": "NCT00841672", "orgStudyIdInfo": {"id": "CSPA100A2306"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension", "officialTitle": "An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients"}, "statusModule": {"statusVerifiedDate": "2011-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-01"}, "primaryCompletionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-10", "studyFirstSubmitQcDate": "2009-02-10", "studyFirstPostDateStruct": {"date": "2009-02-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-05", "resultsFirstSubmitQcDate": "2011-05-26", "resultsFirstPostDateStruct": {"date": "2011-06-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-07-05", "lastUpdatePostDateStruct": {"date": "2011-07-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis that the combination of aliskiren/amlodipine produces a superior reduction from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment."}, "conditionsModule": {"conditions": ["Moderate to Severe Hypertension"], "keywords": ["Hypertension", "systolic blood pressure", "cardiovascular disease", "aliskiren", "amlodipine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 485, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren/amlodipine 300/10 mg tablet", "type": "EXPERIMENTAL", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.", "interventionNames": ["Drug: Aliskiren/amlodipine 300/10 mg tablet"]}, {"label": "Amlodipine 10 mg capsule", "type": "ACTIVE_COMPARATOR", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.", "interventionNames": ["Drug: Amlodipine 10 mg capsule"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren/amlodipine 300/10 mg tablet", "description": "Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.", "armGroupLabels": ["Aliskiren/amlodipine 300/10 mg tablet"]}, {"type": "DRUG", "name": "Amlodipine 10 mg capsule", "description": "Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.", "armGroupLabels": ["Amlodipine 10 mg capsule"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Sitting Systolic Blood Pressure (msSBP)", "description": "Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)", "timeFrame": "Baseline to end of study (Week 8)"}], "secondaryOutcomes": [{"measure": "Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Systolic Blood Pressure Response", "description": "Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \\< 140 mmHg or a reduction =\\> 20 mmHg from the baseline) from baseline to end of study (Week 8)", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Diastolic Blood Pressure Response", "description": "Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \\< 90 mmHg or a reduction \u2265 10 mmHg from the baseline) from baseline to end of study (Week 8)", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Blood Pressure Control", "description": "Percentage of patients achieving blood pressure control (msSBP \\< 140 mm Hg and msDBP \\< 90 mm Hg) at end of study", "timeFrame": "End of study (Week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Outpatients \u2265 18 years of age\n* Patients with a diagnosis of moderate to severe hypertension, defined as msSBP \u2265 160 mmHg and \\< 200 mmHg at Visit 2\n\nExclusion Criteria:\n\n* Mild to moderate hypertension\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential\n* Previous or current diagnosis of heart failure New York Heart Association(NYHA) Class II-IV.\n* Serum potassium \u2265 5.3 mEq/L (mmol/L) at Visit 1.\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures\n* History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention\n* Patients on a combination of 3 or more antihypertensive medications\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigative Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigative Site", "city": "Manilla", "country": "Philippines"}, {"facility": "Investigative Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigative Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigative Site", "city": "Singapore", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Investigative Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "FG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "One patient was mis-randomized and was not treated in the double-blind treatment period.", "numSubjects": "244"}, {"groupId": "FG001", "numSubjects": "241"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "224"}, {"groupId": "FG001", "numSubjects": "209"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Misrandomized", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "BG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "244"}, {"groupId": "BG001", "value": "241"}, {"groupId": "BG002", "value": "485"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59", "spread": "10.38"}, {"groupId": "BG001", "value": "59", "spread": "10.82"}, {"groupId": "BG002", "value": "59", "spread": "10.60"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "139"}, {"groupId": "BG002", "value": "275"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "210"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Sitting Systolic Blood Pressure (msSBP)", "description": "Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)", "populationDescription": "Full Analysis Set - analysis set was the FAS excluding patients from one center due to Good Clinical Practices (GCP) issues", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "OG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "230"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.72", "spread": "0.937"}, {"groupId": "OG001", "value": "-30.63", "spread": "0.941"}]}]}]}, {"type": "SECONDARY", "title": "Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)", "populationDescription": "Full Analysis Set - analysis set was the FAS excluding patients from one center due to Good Clinical Practices (GCP) issues", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "OG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "230"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.10", "spread": "0.557"}, {"groupId": "OG001", "value": "-12.27", "spread": "0.559"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure Response", "description": "Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \\< 140 mmHg or a reduction =\\> 20 mmHg from the baseline) from baseline to end of study (Week 8)", "populationDescription": "Full Analysis Set - analysis set was the FAS excluding patients from one center due to GCP issues", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "OG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "230"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.8"}, {"groupId": "OG001", "value": "79.1"}]}]}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure Response", "description": "Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \\< 90 mmHg or a reduction \u2265 10 mmHg from the baseline) from baseline to end of study (Week 8)", "populationDescription": "Full Analysis Set - analysis set was the FAS excluding patients from one center due to Good Clinical Practices (GCP) issues All randomized patients who received the study medication. The measurement at Week 8 was used unless it was not available, in which case, the last observation carried forward was used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "OG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "230"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92.7"}, {"groupId": "OG001", "value": "86.5"}]}]}]}, {"type": "SECONDARY", "title": "Blood Pressure Control", "description": "Percentage of patients achieving blood pressure control (msSBP \\< 140 mm Hg and msDBP \\< 90 mm Hg) at end of study", "populationDescription": "Full Analysis Set - analysis set was the FAS excluding patients from one center due to Good Clinical Practices (GCP) issues", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."}, {"id": "OG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "230"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.0"}, {"groupId": "OG001", "value": "49.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren/Amlodipine 300/10 mg Tablet", "description": "Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.", "seriousNumAffected": 0, "seriousNumAtRisk": 243, "otherNumAffected": 41, "otherNumAtRisk": 243}, {"id": "EG001", "title": "Amlodipine 10 mg Capsule", "description": "Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.", "seriousNumAffected": 3, "seriousNumAtRisk": 241, "otherNumAffected": 56, "otherNumAtRisk": 241}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 241}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 241}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 241}]}, {"term": "Adenomyosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 241}]}, {"term": "Dysfunctional uterine bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 241}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 241}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 243}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 241}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}